NEW YORK, Nov. 10, 2014 /PRNewswire/ -- There is a continuing trend toward the use of molecular diagnostics in the screening of donated blood, and as a result sales of newer nucleic acid tests are growing briskly, according to Kalorama Information. The healthcare market researcher's report, Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products, notes that from 2013 to 2018 global sales of nucleic acid tests will increase by 11.8% from $1.7 billion to about $3.1 billion.
The report can be found at KI:
http://www.kaloramainformation.com/redirect.asp?progid=86835&productid=8437179.
"Due to their lower cost, immunoassays or in-lab developed PCR tests had tended to be used more frequently in developing nations while nucleic acid testing were used predominantly in developed countries, but this is changing," said Alison Sahoo, the author of Kalorama's report.
Nucleic acid testing (NAT), a newer technology also known as "molecular diagnostics," has allowed blood banks to detect viral contamination – from the likes of West Nile virus, HIV and hepatitis C – sooner and prevented these viruses from slipping into blood transfusions, and so has now become an integral part of the concerted effort to make blood transfusions safer.
Blood banking in vitro diagnostics (IVD) – blood testing – is required of all donated blood, a necessary screening measure to keep blood supplies safe. A variety of infectious agents can be present in blood, including viruses, bacteria, protozoans, Chagas disease, and Lyme disease. Nonetheless, blood safety is relatively high, due to the widespread usage of blood testing. The testing markets covered in Kalorama's report include those of human immunodeficiency virus (HIV), hepatitis A virus, hepatitis B virus, hepatitis C virus, human T-cell leukemia virus, West Nile virus and others.
In 2001, the FDA licensed the first NAT systems for screening of plasma donors with the expectation that NAT would permit earlier detection of HIV and HCV infections in donors. NAT allows detection of very small amounts of genetic material (DNA or RNA), allowing highly sensitive detection of targets. This has resulted in lower rates of infectious disease transmission.
Blood: The Worldwide Market provides an analysis of all the key blood market segments involved in this industry, including products, equipment and testing. In addition to complete market data, including forecasts to 2018, the study reports product demand estimates by region, collection and transfusion estimates, high-blood-loss procedure estimates, product pricing, reimbursement rates and products on the market and in development. The report also provides discussion of key trends, as well as the regulatory, business, and clinical challenges facing the various sectors of the blood industry. The report also profiles key companies in the industry.
Specifically excluded from this report are blood testing products not used primarily for blood donation and collection. For example, tests for blood banking represent about 12% of all immunoassay infectious disease tests (which include tests for HIV, hepatitis B and C and syphilis) and about one quarter of all nucleic acid tests (which include assays for West Nile Virus, HIV and hepatitis C).
For more information on Blood: The Worldwide Market and other reports in Kalorama's industry leading research, please visit: http://www.kaloramainformation.com/.
About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article